LAVA Therapeutics NV
NASDAQ:LVTX
LAVA Therapeutics NV
Operating Expenses
LAVA Therapeutics NV
Operating Expenses Peer Comparison
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Operating Expenses
-$46.5m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
AEX:PHARM
|
Operating Expenses
-$241.9m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-34%
|
|
Uniqure NV
NASDAQ:QURE
|
Operating Expenses
-$285.1m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-23%
|
|
argenx SE
XBRU:ARGX
|
Operating Expenses
-$1.5B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-68%
|
CAGR 10-Years
N/A
|
|
Merus NV
NASDAQ:MRUS
|
Operating Expenses
-$200.5m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Operating Expenses
-€101.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is LAVA Therapeutics NV's Operating Expenses?
Operating Expenses
-46.5m
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Operating Expenses amounts to -46.5m USD.
What is LAVA Therapeutics NV's Operating Expenses growth rate?
Operating Expenses CAGR 3Y
-36%
Over the last year, the Operating Expenses growth was 14%. The average annual Operating Expenses growth rates for LAVA Therapeutics NV have been -36% over the past three years .